Table 5.

Association of baseline characteristics and treatment group assignment with diuretic dose escalation during 52 weeks of follow-up

Predictor	Odds ratio (95% CI)	P-value
Treatment (semaglutide 2.4 mg vs. placebo)	0.36 (0.23–0.55)	<.0001
NYHA class (III/IV vs. II)	1.99 (1.34–2.96)	.0007
LV ejection fraction (per 1%-unit increase)	0.97 (0.95–1.00)	.07
Atrial fibrillation	1.60 (1.07–2.40)	.02
Obstructive sleep apnoea	2.27 (1.31–3.93)	.003
SGLT2 inhibitor use	0.59 (0.34–1.04)	.07
ACE inhibitor/ARB/ARNi use	0.53 (0.34–0.83)	.006
Insulin and analogues	2.91 (1.68–5.05)	.0001

NYHA, New York Heart Association; LV, left ventricular; SGLT2, sodium–glucose cotransporter 2; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor.